The Journal of clinical endocrinology and metabolism
The most recent articles from:
November 1993
-
J. Clin. Endocrinol. Metab. · Nov 1993
Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486.
Treatment of nude mice bearing xenografts of the human malignant glioma U87MG cell line with the steroid hormone antagonist RU486 for 4 weeks resulted in a significant and dose-dependent suppression of tumor volume and weight. Receptor analyses of tumor cytosol preparations demonstrated a single class of high affinity binding sites for dexamethasone, but the absence of receptors for progesterone. ⋯ The antiproliferative effect of RU486 appears to be due to the inhibition of binding of glucocorticoid hormones to their receptor proteins. Our results suggest a new therapy for some brain tumors, such as malignant gliomas based on the steroid hormone antagonist RU486.